Dr. Robert B. Bhisitkul, MD

Dr. Bhisitkul practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Bhisitkul's NPI, 1831138676, was assigned on June 6, 2006. Dr. Bhisitkul graduated from Stanford University School Of Medicine in 1992. Dr. Bhisitkul holds California license G84511.

Dr. Bhisitkul's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Bhisitkul's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. Dr. Bhisitkul is also affiliated with California Pacific Medical Center Davies Campus. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Bhisitkul to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bhisitkul practices, 4 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Bhisitkul's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Bhisitkul is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Bhisitkul's licenses on file in 2 states: California and Massachusetts.

Dmand AI lists age-related macular degeneration, cataract, dry eye, glaucoma, hypertensive retinopathy, laser destruction of retinal or choroid lesions, retinal detachment and retinal occlusion among the conditions Dr. Bhisitkul treats.

CMS data shows 2,042 Medicare services from Dr. Bhisitkul across 7 procedure codes in 2024, for 464 Medicare patients. Medicare paid $97,919 for them.

CMS counts 464 Medicare patients who saw Dr. Bhisitkul in 2024. The largest group is 65 to 74, with 182 patients. 72% of them have high cholesterol, and 70% have high blood pressure. 36% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bhisitkul's median patient age at 73, with 53% women.

In 2024, Dr. Bhisitkul wrote 166 Medicare Part D claims for 50 patients. 61% of them were for generic drugs. CMS names the drug for 116 of them, across 5 drugs with 11 or more claims each, at $3,085 in total drug cost. In 2023, CMS named 132 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Bhisitkul for performance year 2024, reported as part of a group. Dr. Bhisitkul accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 52 papers to Dr. Bhisitkul, published from 2007 to 2025. 2019 was the busiest year, with 3. The most frequent topics are Visual Acuity, Angiogenesis Inhibitors and Fluorescein Angiography. Dr. Bhisitkul has published most often in Ophthalmology. Dr. Bhisitkul's most frequent co-authors are Tejal Desai, DO, Peter Anthony Campochiaro, MD and Soraya Rofagha, MD.

Dmand AI links Dr. Bhisitkul to 2 clinical trials. Conditions studied include Geographic Atrophy, Glaucoma and Macular Degeneration. University of California, San Francisco sponsors the most, 2.

CMS Open Payments shows 76 general payments to Dr. Bhisitkul from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 54% of the total. Genentech, Inc. paid the most, $17,400. It also lists 5 research payments totaling $9,433 from 2020 to 2022.

Dmand AI lists 2 awards for Dr. Bhisitkul, most recently AAO Fellow in 2013.

Dr. Bhisitkul graduated from Stanford University School Of Medicine in 1992. Dr. Bhisitkul is a member of AAO.

Dr. Bhisitkul is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.